A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
Status:
Completed
Trial end date:
2015-09-21
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, single sequence, two-way interaction study in healthy male and
female subjects. For the effect of maraviroc on the pharmacokinetics (PK) of BMS-626529 (the
active moiety of BMS-663068), there is no formal hypothesis to be statistically tested. The
purpose of this assessment is to estimate the effect of maraviroc on the PK of BMS-626529
when coadministered in healthy subjects. For the effect of BMS-663068 on the PK of maraviroc,
the hypothesis to be statistically tested is that BMS-663068 will not have a clinically
significant effect on the PK of maraviroc when coadministered in healthy subjects.